Evidence map›Paper›PMID 40760233›Full record

ArticleInvestigational new drugs2025

Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells.

Cai-Chieh Tseng, Min-Hsi Ku, Wei-Min Wu, Ava Mendez, Tessa Christner, Yun-Chieh Wu, Wei-Lun Huang, Yu-Hsiang Chen, Ching-Wen Huang, Johnathan Barefoot and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigational new drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Cai-Chieh TsengDepartment of Biochemical and Molecular Medical Sciences, College of Science and Engineering, National Dong Hwa University, Hualien, 974301, Taiwan, R.O.C.
Min-Hsi KuDepartment of Biochemical and Molecular Medical Sciences, College of Science and Engineering, National Dong Hwa University, Hualien, 974301, Taiwan, R.O.C.
Wei-Min WuDepartment of Natural Resources and Environmental Studies, College of Environmental Studies, National Dong Hwa University, Hualien, 974301, Taiwan, R.O.C.
Ava MendezDepartment of Biology, College of Arts and Sciences, Appalachian State University, Boone, NC, 28608, USA.
Tessa ChristnerDepartment of Biology, College of Arts and Sciences, Appalachian State University, Boone, NC, 28608, USA.
Yun-Chieh WuDepartment of Biochemical and Molecular Medical Sciences, College of Science and Engineering, National Dong Hwa University, Hualien, 974301, Taiwan, R.O.C.
Wei-Lun HuangDepartment of Biochemical and Molecular Medical Sciences, College of Science and Engineering, National Dong Hwa University, Hualien, 974301, Taiwan, R.O.C.
Yu-Hsiang ChenDepartment of Biochemical and Molecular Medical Sciences, College of Science and Engineering, National Dong Hwa University, Hualien, 974301, Taiwan, R.O.C.
Ching-Wen HuangDepartment of Biochemical and Molecular Medical Sciences, College of Science and Engineering, National Dong Hwa University, Hualien, 974301, Taiwan, R.O.C.
Johnathan BarefootDepartment of Biology, College of Arts and Sciences, Appalachian State University, Boone, NC, 28608, USA.
Chi-Wei ChenDepartment of Biochemical and Molecular Medical Sciences, College of Science and Engineering, National Dong Hwa University, Hualien, 974301, Taiwan, R.O.C.. chenc4@appstate.edu.

Funding

National Science and Technology Council 111-2320-B-259-001
6 · The paper itself

Abstract

Ovarian cancer remains one of the most lethal gynecologic malignancies, largely due to high recurrence rates and treatment-related toxicities. Although PARP inhibitors like Olaparib have shown efficacy in BRCA-mutated cancers, their benefit is limited in broader patient populations. TP53 mutations, highly prevalent in ovarian cancer, promote tumor progression and resistance, making p53 a key therapeutic target. This study evaluated the anticancer potential of HO-3867, a curcumin analog known to restore mutant p53 function, alone and in combination with Olaparib. We used fallopian tube-derived ovarian cancer models harboring mutant or null TP53 and analyzed TP53 expression and mutation profiles using TCGA datasets. Molecular docking simulations and cellular thermal shift assays (CETSA) confirmed HO-3867 binding to the p53

Indexed as

Antineoplastic AgentsCurcuminEpithelial CellsFallopian Tube NeoplasmsOvarian NeoplasmsPhthalazinesPiperazinesApoptosisCell Line, TumorCell ProliferationDNA DamageDrug SynergismFemaleHumansMolecular Docking SimulationMutationAntineoplastic AgentsCurcuminolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsTP53 protein, humanTumor Suppressor Protein p53Curcumin analogHO-3867Ovarian cancerPARP inhibitorTP53Transforming fallopian tube epithelial cells

Identifiers

PMID40760233
PMCPMC12515124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.